Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia

Maria Ilaria Del Principe, Giovanni Del Poeta, Adriano Venditti, Francesco Buccisano, Luca Maurillo, Rita Marini, Maria Christina Cox, Paola Panetta, Giovanna Suppo, Massimo Degan, Antonio Bruno, Valter Gattei, Sergio Amadori

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and Objectives. p53 status and CD38 antigen are biological factors influencing response to therapy and clinical course in B-cell chronic lymphocytic leukemia (B-CLL). This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis. Design and Methods. Wild and mutant forms of p53 protein were evaluated in 197 B-CLL patients at diagnosis or before progression by an immunoenzymatic method in plasma using an anti-p53 monoclonal antibody. CD38 expression was analyzed by a multicolor flow cytometric assay. Results. Higher levels of both soluble p53 (sp53) and CD38 were significantly correlated with intermediate and high Rai stages, with higher β2-microglobulin and soluble CD23 values, determined at diagnosis. Shorter overall survival (OS) and progression-free survival (PFS) were both observed in sp53+ and CD38+ patients (p 60 years) were independent prognostic factors whereas sp53 showed only a tendency towards statistical significance.

Original languageEnglish
Pages (from-to)1468-1475
Number of pages8
JournalHaematologica
Volume89
Issue number12
Publication statusPublished - Dec 2004

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
CD38 Antigens
Tumor Suppressor Protein p53
Biological Factors
Disease-Free Survival
Monoclonal Antibodies
Survival
IgA receptor
Proteins
Therapeutics

Keywords

  • B-CLL
  • CD38
  • Prognosis
  • Soluble p53

ASJC Scopus subject areas

  • Hematology

Cite this

Ilaria Del Principe, M., Del Poeta, G., Venditti, A., Buccisano, F., Maurillo, L., Marini, R., ... Amadori, S. (2004). Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica, 89(12), 1468-1475.

Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. / Ilaria Del Principe, Maria; Del Poeta, Giovanni; Venditti, Adriano; Buccisano, Francesco; Maurillo, Luca; Marini, Rita; Cox, Maria Christina; Panetta, Paola; Suppo, Giovanna; Degan, Massimo; Bruno, Antonio; Gattei, Valter; Amadori, Sergio.

In: Haematologica, Vol. 89, No. 12, 12.2004, p. 1468-1475.

Research output: Contribution to journalArticle

Ilaria Del Principe, M, Del Poeta, G, Venditti, A, Buccisano, F, Maurillo, L, Marini, R, Cox, MC, Panetta, P, Suppo, G, Degan, M, Bruno, A, Gattei, V & Amadori, S 2004, 'Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia', Haematologica, vol. 89, no. 12, pp. 1468-1475.
Ilaria Del Principe M, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Marini R et al. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica. 2004 Dec;89(12):1468-1475.
Ilaria Del Principe, Maria ; Del Poeta, Giovanni ; Venditti, Adriano ; Buccisano, Francesco ; Maurillo, Luca ; Marini, Rita ; Cox, Maria Christina ; Panetta, Paola ; Suppo, Giovanna ; Degan, Massimo ; Bruno, Antonio ; Gattei, Valter ; Amadori, Sergio. / Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. In: Haematologica. 2004 ; Vol. 89, No. 12. pp. 1468-1475.
@article{e0336b899aa54f309f857fccfb17a64f,
title = "Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia",
abstract = "Background and Objectives. p53 status and CD38 antigen are biological factors influencing response to therapy and clinical course in B-cell chronic lymphocytic leukemia (B-CLL). This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis. Design and Methods. Wild and mutant forms of p53 protein were evaluated in 197 B-CLL patients at diagnosis or before progression by an immunoenzymatic method in plasma using an anti-p53 monoclonal antibody. CD38 expression was analyzed by a multicolor flow cytometric assay. Results. Higher levels of both soluble p53 (sp53) and CD38 were significantly correlated with intermediate and high Rai stages, with higher β2-microglobulin and soluble CD23 values, determined at diagnosis. Shorter overall survival (OS) and progression-free survival (PFS) were both observed in sp53+ and CD38+ patients (p 60 years) were independent prognostic factors whereas sp53 showed only a tendency towards statistical significance.",
keywords = "B-CLL, CD38, Prognosis, Soluble p53",
author = "{Ilaria Del Principe}, Maria and {Del Poeta}, Giovanni and Adriano Venditti and Francesco Buccisano and Luca Maurillo and Rita Marini and Cox, {Maria Christina} and Paola Panetta and Giovanna Suppo and Massimo Degan and Antonio Bruno and Valter Gattei and Sergio Amadori",
year = "2004",
month = "12",
language = "English",
volume = "89",
pages = "1468--1475",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia

AU - Ilaria Del Principe, Maria

AU - Del Poeta, Giovanni

AU - Venditti, Adriano

AU - Buccisano, Francesco

AU - Maurillo, Luca

AU - Marini, Rita

AU - Cox, Maria Christina

AU - Panetta, Paola

AU - Suppo, Giovanna

AU - Degan, Massimo

AU - Bruno, Antonio

AU - Gattei, Valter

AU - Amadori, Sergio

PY - 2004/12

Y1 - 2004/12

N2 - Background and Objectives. p53 status and CD38 antigen are biological factors influencing response to therapy and clinical course in B-cell chronic lymphocytic leukemia (B-CLL). This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis. Design and Methods. Wild and mutant forms of p53 protein were evaluated in 197 B-CLL patients at diagnosis or before progression by an immunoenzymatic method in plasma using an anti-p53 monoclonal antibody. CD38 expression was analyzed by a multicolor flow cytometric assay. Results. Higher levels of both soluble p53 (sp53) and CD38 were significantly correlated with intermediate and high Rai stages, with higher β2-microglobulin and soluble CD23 values, determined at diagnosis. Shorter overall survival (OS) and progression-free survival (PFS) were both observed in sp53+ and CD38+ patients (p 60 years) were independent prognostic factors whereas sp53 showed only a tendency towards statistical significance.

AB - Background and Objectives. p53 status and CD38 antigen are biological factors influencing response to therapy and clinical course in B-cell chronic lymphocytic leukemia (B-CLL). This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis. Design and Methods. Wild and mutant forms of p53 protein were evaluated in 197 B-CLL patients at diagnosis or before progression by an immunoenzymatic method in plasma using an anti-p53 monoclonal antibody. CD38 expression was analyzed by a multicolor flow cytometric assay. Results. Higher levels of both soluble p53 (sp53) and CD38 were significantly correlated with intermediate and high Rai stages, with higher β2-microglobulin and soluble CD23 values, determined at diagnosis. Shorter overall survival (OS) and progression-free survival (PFS) were both observed in sp53+ and CD38+ patients (p 60 years) were independent prognostic factors whereas sp53 showed only a tendency towards statistical significance.

KW - B-CLL

KW - CD38

KW - Prognosis

KW - Soluble p53

UR - http://www.scopus.com/inward/record.url?scp=10444268007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444268007&partnerID=8YFLogxK

M3 - Article

C2 - 15590397

AN - SCOPUS:10444268007

VL - 89

SP - 1468

EP - 1475

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 12

ER -